EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

被引：15

作者：

Tao, Zhonfei ^{[1
,2
,3
,5
]}

Liu, Bingcheng ^{[1
,2
,3
]}

Zhao, Yaozhong ^{[1
,2
,3
]}

Wang, Ying ^{[1
,2
,3
]}

Zhang, Rongli ^{[1
,2
,3
]}

Han, Mingzhe ^{[1
,2
,3
]}

Zhang, Li ^{[1
,2
,3
]}

Li, Chengwen ^{[2
,3
,4
]}

Ru, Kun ^{[2
,3
,4
]}

Mi, Yingchang ^{[1
,2
,3
]}

Wang, Jianxiang ^{[1
,2
,3
,5
]}

机构：

[1] Chinese Acad Med Sci, Dept Clin Hematol, Inst Hematol, Tianjin 300020, Peoples R China

[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China

[3] Peking Union Med Coll, Tianjin 300020, Peoples R China

[4] Chinese Acad Med Sci, Dept Hemopathol, Inst Hematol, Tianjin 300020, Peoples R China

[5] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China

来源：

LEUKEMIA RESEARCH | 2014年 / 38卷 / 09期

基金：

中国国家自然科学基金;

关键词：

EUTOS; Chronic myeloid leukemia; Complete cytogenetic response; Overall survival; Progression free survival; Prognosis; PATIENTS RECEIVING IMATINIB; TYROSINE KINASE INHIBITORS; EUROPEAN TREATMENT; PROGNOSTIC SCORE; FOLLOW-UP; CML; FRONTLINE; RECOMMENDATIONS; RESISTANCE; THERAPY;

D O I：

10.1016/j.leukres.2014.06.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sokal, Euro and newly developed EUTOS scoring systems were validated in 220 Chinese chronic phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib. In the EUTOS low-risk and high-risk groups, the 5-year OS was 98.7% vs. 71.4% (P<0.0001), and the 5-year cumulative incidence of complete cytogenetic response (CCyR) was 92.4% vs. 53.8% (p<0.0001). EUTOS score also predicted progression-free survival and duration of CCyR. Low EUTOS index predicted for CCyR. However, Sokal and Euro scores mainly could not discriminate the intermediate-risk from high-risk group in either survival or CCyR. EUTOS score forecasts the prognosis of CP-CML patients treated with first-line imatinib. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：1030 / 1035

页数：6

共 50 条

[21] Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
Cojbasic, Irena
Macukanovic-Golubovic, Lana
VOJNOSANITETSKI PREGLED, 2011, 68 (11) : 911 - 916
[22] LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients
Shehata, Amira M. F.
Gohar, Suzy F.
Muharram, Nashwa M.
Eldin, Samar M. Kamal
LEUKEMIA RESEARCH, 2022, 116
[23] Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy
Khoury, Hanna J.
Bixby, Dale L.
LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 568 - 576
[24] Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis
Thota, N. K.
Gundeti, S.
Linga, V. G.
Coca, P.
Tara, R. P.
Raghunadharao
INDIAN JOURNAL OF CANCER, 2014, 51 (01) : 5 - 9
[25] Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
Song, Moo-Kon
Chung, Joo-Seop
Seol, Young-Mi
Kim, Seong-Geun
Shin, Ho-Jin
Choi, Young-Jin
Cho, Goon-Jae
LEUKEMIA RESEARCH, 2009, 33 (11) : 1459 - 1462
[26] Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, Timothy P.
Saglio, Giuseppe
Kantarjian, Hagop M.
Guilhot, Francois
Niederwieser, Dietger
Rosti, Gianantonio
Nakaseko, Chiaki
De Souza, Carmino Antonio
Kalaycio, Matt E.
Meier, Stephan
Fan, Xiaolin
Menssen, Hans D.
Larson, Richard A.
Hochhaus, Andreas
BLOOD, 2014, 123 (09) : 1353 - 1360
[27] Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience
Al-Amri, Ali M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (03) : 199 - 203
[28] Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib
Roche-Lestienne, C
Darré, S
Laï, DL
Facon, T
Guilhot, J
Preudhomme, C
HAEMATOLOGICA, 2005, 90 (01) : 131 - 133
[29] The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure
Jabbour, Elias
Kantarjian, Hagop
Ghanem, Hady
O'Brien, Susan
Quintas-Cardama, Alfonso
Garcia-Manero, Guillermo
Cardenas, Marylou
Cortes, Jorge
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03) : 302 - 306
[30] Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil
Silveira, C. A. P.
Daldegan, M. B.
Ferrari, I.
GENETICS AND MOLECULAR RESEARCH, 2011, 10 (03) : 2038 - 2048

← 1 2 3 4 5 →